Vise Technologies Inc. Makes New $899,000 Investment in United Therapeutics Corporation $UTHR

Vise Technologies Inc. purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,659 shares of the biotechnology company’s stock, valued at approximately $899,000.

Other institutional investors have also modified their holdings of the company. Leuthold Group LLC increased its holdings in United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares during the period. UBS Group AG boosted its stake in shares of United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares during the period. Nicholas Investment Partners LP boosted its stake in shares of United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after buying an additional 3,766 shares during the period. M&T Bank Corp grew its position in shares of United Therapeutics by 171.6% during the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after buying an additional 1,985 shares in the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in shares of United Therapeutics during the fourth quarter worth about $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $513.12 on Monday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The company has a market cap of $22.01 billion, a P/E ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59. The business’s 50-day simple moving average is $533.08 and its 200-day simple moving average is $537.80.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 earnings per share. As a group, analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,729.06. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. This trade represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 442,575 shares of company stock worth $239,326,330 over the last quarter. 8.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.